2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group
Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2021, 112: 890-900. PMID: 34767937, PMCID: PMC9038118, DOI: 10.1016/j.ijrobp.2021.10.152.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapySlow early responseClassical Hodgkin lymphomaBulky diseaseOncology GroupHodgkin's lymphomaRetrospective analysisChildren's Oncology Group protocolsHigh-risk Hodgkin lymphomaRadiation treatment volumesCycles of doxorubicinHigh-risk patientsPhase 3 studyTime of progressionChildren's Oncology GroupPatterns of failureInitial siteABVE-PCConsolidation RTEligible patientsField relapseInitial relapseMedian followRelapse siteStage IIIB
2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patientsNCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFL
2017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volumeNCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens
2016
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II
Dhakal S, Advani R, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. American Journal Of Clinical Oncology 2016, 39: 535-544. PMID: 27643717, PMCID: PMC7433865, DOI: 10.1097/coc.0000000000000331.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDisease-Free SurvivalDose-Response Relationship, DrugFemaleHodgkin DiseaseHumansMaleNeoplasm InvasivenessNeoplasm StagingOutcome Assessment, Health CarePractice Guidelines as TopicRadiotherapy DosageRandomized Controlled Trials as TopicRisk AssessmentSocieties, MedicalSurvival AnalysisUnited StatesConceptsStage IModality therapyHodgkin's lymphomaAppropriateness CriteriaMedical literatureAppropriateness of imagingACR Appropriateness CriteriaRadiology Appropriateness CriteriaEvidence-based guidelinesMultidisciplinary expert panelSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literatureLess chemotherapyPeer-reviewed journalsLate effectsClinical conditionsRadiation therapyAmerican CollegeExpert opinionClinical scenariosExcellent efficacyGuideline developmentAvailable evidenceAdjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factorsACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
2014
Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality
2013
ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology 2013, 27: 786-94. PMID: 24133827.Peer-Reviewed Original ResearchMeSH KeywordsDiagnostic ImagingHumansLymphomaLymphoma, Non-HodgkinNeoplasm StagingPractice Guidelines as TopicRadiologyConceptsIndolent lymphomaAppropriateness of imagingOutcomes of patientsMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsPeer-reviewed journalsPrognostic factorsTreatment optionsAppropriateness CriteriaTreatment decisionsClinical conditionsAmerican CollegeGuideline developmentMedical literatureRadiation guidelinesConsensus methodologyLymphomaExpert panelRadiation dosePatientsRadiation techniques
2012
Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2011
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers
Chen Z, Roberts K, Decker R, Pathare P, Rockwell S, Nath R. The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Physics In Medicine And Biology 2011, 56: 4895-4912. PMID: 21772076, PMCID: PMC3154133, DOI: 10.1088/0031-9155/56/15/016.Peer-Reviewed Original ResearchConceptsPermanent interstitial brachytherapyProstate edemaProstate cancerEffects of edemaTumor control probabilityImpact of edemaInterstitial brachytherapyCell survivalEarly-stage prostate cancerControl probabilityStage prostate cancerCurrent clinical practiceProstate cancer cellsTumor cell proliferationInterstitial brachytherapy treatmentSublethal damage repairDose variationTumor cell survivalTumor characteristicsTumor controlClinical impactEdemaEdema evolutionClinical practiceProstate gland
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalitiesInterim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix
Roberts K, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S, Sartorelli A, Fischer D, Fischer J. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix. International Journal Of Cancer 2000, 90: 206-223. PMID: 10993961, DOI: 10.1002/1097-0215(20000820)90:4<206::aid-ijc4>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaDisease-free survivalMitomycin CSurvival rateRadical radiotherapyCervix cancerActuarial disease-free survival rateLocal recurrence-free survival rateActuarial disease-free survivalAdvanced squamous cell carcinomaOpen phase III trialDisease-free survival ratesRecurrence-free survival ratesDistant recurrence-free survivalAcute radiation reactionsIII-IVA patientsIntravenous mitomycin CMild hematologic toxicityNon-hematologic toxicitiesTreatment-related deathsActuarial survival rateAdvanced stage diseasePhase III trialsMitomycin C groupRecurrence-free survival
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancerEffective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy
Turner B, Knisely J, Kacinski B, Haffty B, Gumbs A, Roberts K, Frank A, Peschel R, Rutherford T, Edraki B, Kohorn E, Chambers S, Schwartz P, Wilson L. Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 77-84. PMID: 9422561, DOI: 10.1016/s0360-3016(97)00581-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyChemotherapy, AdjuvantCystadenocarcinoma, PapillaryDisease-Free SurvivalFemaleHumansHysterectomyMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesSalvage TherapyUterine NeoplasmsConceptsUterine papillary serous carcinomaWhole pelvic radiation therapyWhole-abdomen radiation therapyComplete surgical stagingDisease-free survivalActuarial disease-free survivalFIGO stage IPapillary serous carcinomaSurgical stagingActuarial OSOverall survivalSalvage rateStage IRadiation therapyUPSC patientsVaginal brachytherapyMyometrial invasionSerous carcinomaLDR brachytherapyRadiation Therapy Oncology Group (RTOG) grade 1DFS of patientsPara-aortic lymph node samplingConventional external beam radiotherapyFIGO stage IARTOG grade 3
1996
Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
Fishman D, Roberts K, Chambers J, Kohorn E, Schwartz P, Chambers S. Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium. Gynecologic Oncology 1996, 61: 189-196. PMID: 8626131, DOI: 10.1006/gyno.1996.0123.Peer-Reviewed Original ResearchConceptsClinical stage IOperable patientsInoperable patientsIntercurrent diseaseStage IRadiation therapyMedian survivalEndometrioid carcinomaMore deathsMedian disease-free intervalExclusive radiation therapyMedically Inoperable PatientsStage I groupCancer-specific survivalDisease-free intervalStage II diseaseOverall survival rateShorter overall survivalOperable diseaseOperable groupEndometrial cancerOverall survivalSuch patientsShorter survivalClinical stage